SUMATRIPTAN AND NAPROXEN SODIUM Drug Patent Profile
When do Sumatriptan And Naproxen Sodium patents expire, and what generic alternatives are available?
Sumatriptan And Naproxen Sodium is a drug marketed by Aurobindo Pharma Ltd, Rising, and Sun Pharm. and is included in three NDAs.
The generic ingredient in SUMATRIPTAN AND NAPROXEN SODIUM is naproxen sodium; sumatriptan succinate. There is one drug master file entry for this compound. Five suppliers are listed for this compound. Additional details are available on the naproxen sodium; sumatriptan succinate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SUMATRIPTAN AND NAPROXEN SODIUM?
- What are the global sales for SUMATRIPTAN AND NAPROXEN SODIUM?
- What is Average Wholesale Price for SUMATRIPTAN AND NAPROXEN SODIUM?
Summary for SUMATRIPTAN AND NAPROXEN SODIUM
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 3 |
| Clinical Trials: | 25 |
| DailyMed Link: | SUMATRIPTAN AND NAPROXEN SODIUM at DailyMed |
Recent Clinical Trials for SUMATRIPTAN AND NAPROXEN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Beijing Friendship Hospital | Phase 3 |
| The Third Xiangya Hospital of Central South University | Phase 3 |
| The First Affiliated Hospital of Guangzhou Medical University | Phase 3 |
Pharmacology for SUMATRIPTAN AND NAPROXEN SODIUM
US Patents and Regulatory Information for SUMATRIPTAN AND NAPROXEN SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aurobindo Pharma Ltd | SUMATRIPTAN AND NAPROXEN SODIUM | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 207457-001 | Feb 15, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Rising | SUMATRIPTAN AND NAPROXEN SODIUM | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 090872-001 | Sep 4, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sun Pharm | SUMATRIPTAN AND NAPROXEN SODIUM | naproxen sodium; sumatriptan succinate | TABLET;ORAL | 202803-001 | Jul 20, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Sumatriptan and Naproxen Sodium Market Dynamics, Patent Status, and Financial Trajectory
Sumatriptan and naproxen sodium is a fixed-dose oral migraine treatment commercialized in the United States as Treximet. The product combines the 5-HT1B/1D agonist sumatriptan with the nonsteroidal anti-inflammatory drug naproxen sodium. Its commercial position has weakened since U.S. patent protection ended and generic versions entered the market. The product remains differentiated by combination convenience, but generic substitution, lower-cost triptan alternatives, CGRP therapies, and payer pressure limit revenue growth.
Treximet received U.S. Food and Drug Administration approval in April 2008 under NDA 021926. The original commercial rights moved from GlaxoSmithKline to other specialty-pharmaceutical owners, including Pernix and later Assertio. The market has shifted from an originator-led product to a multi-source generic market with limited pricing power.
What is the market status of sumatriptan and naproxen sodium?
Sumatriptan and naproxen sodium is an oral, fixed-dose combination indicated for the acute treatment of migraine attacks with or without aura in adults and adolescents aged 12 years and older. The marketed strength is 85 mg sumatriptan and 500 mg naproxen sodium per tablet.[1]
| Attribute | Product data |
|---|---|
| Brand | Treximet |
| Active ingredients | Sumatriptan succinate equivalent to 85 mg sumatriptan; naproxen sodium 500 mg |
| Dosage form | Immediate-release oral tablet |
| Original developer | Pozen |
| Original commercial partner | GlaxoSmithKline |
| FDA approval | April 15, 2008 |
| NDA | 021926 |
| Indication | Acute treatment of migraine in adults and adolescents 12 and older |
| Maximum labeled dose | Two tablets in 24 hours, separated by at least two hours |
| Regulatory category | Small-molecule prescription drug |
| Current market structure | Brand plus multiple generic suppliers |
The product targets patients who require both migraine-specific vasoconstriction and anti-inflammatory analgesia. Its clinical proposition is convenience: one tablet replaces separate administration of a triptan and an NSAID. That advantage is weaker when physicians can prescribe inexpensive generic sumatriptan and generic naproxen separately.
How does sumatriptan and naproxen sodium compare with competing migraine drugs?
The combination competes across three segments: generic triptans, branded oral CGRP products, and non-oral rescue therapies.
| Therapy | Primary differentiation | Pricing pressure | Competitive effect on Treximet |
|---|---|---|---|
| Generic sumatriptan | Low-cost migraine-specific therapy | Very high | Strong substitute |
| Generic sumatriptan plus naproxen | Equivalent two-drug regimen | Very high | Direct clinical substitute |
| Treximet | Single-tablet combination | Moderate to high | Retains convenience niche |
| Rizatriptan, naratriptan, eletriptan generics | Alternative triptans | High | Expands substitution |
| Ubrelvy, Nurtec ODT, Zavzpret | CGRP-pathway acute therapies | Lower generic pressure, higher list prices | Compete for patients needing non-vasoconstrictive options |
| Reyvow | Ditans, non-vasoconstrictive mechanism | Branded pricing | Alternative for selected patients |
| Dihydroergotamine products | Rescue therapy, often non-oral | Variable | Limited direct overlap |
The most important commercial substitute is the separate use of generic sumatriptan and naproxen. Treximet may improve adherence for some patients, but the combination carries the economic disadvantage of a branded or higher-cost fixed-dose product.
CGRP antagonists have changed the treatment landscape. They avoid the vasoconstrictive mechanism associated with triptans and can be used in patients who do not respond adequately to triptans or who have contraindications. Their higher acquisition cost supports continued payer controls, including prior authorization and step therapy. Those controls can preserve a lower-cost role for generic Treximet while restricting premium branded use.
When did Treximet lose exclusivity and patent protection?
Treximet’s principal U.S. patent protection expired in the late 2010s. The original combination patent, U.S. Patent No. 6,060,499, was listed for the product and had an expiration date in 2017, subject to applicable pediatric-exclusivity treatment and regulatory timing.[2]
| Protection category | Timing | Commercial effect |
|---|---|---|
| FDA approval | 2008 | Originator launch |
| New chemical entity exclusivity | Not applicable to the full combination in the same manner as a new molecular entity | Limited standalone exclusivity value |
| Key composition/use patent | 2017 expiration period | Removed the principal barrier to generic entry |
| Pediatric exclusivity | Extended applicable period after patent expiration | Delayed some generic commercial timing |
| Generic entry | Began after patent and regulatory barriers cleared | Initiated price erosion |
| Current status | Mature multi-source market | Low brand leverage |
The product’s market exclusivity was never equivalent to that of a newly discovered active pharmaceutical ingredient. Both sumatriptan and naproxen were established ingredients before Treximet’s approval. The commercial value came from the fixed-dose combination, formulation, and clinical positioning rather than molecular novelty.
What patents protect sumatriptan and naproxen sodium?
The most relevant protection historically covered the combination of sumatriptan and naproxen for migraine treatment. The principal patent estate did not create a durable barrier after the late-2010s expiration period.
Composition and method-of-use patents
Treximet’s patent strategy relied on claims directed to:
- Combining sumatriptan or a pharmaceutically acceptable salt with naproxen or a pharmaceutically acceptable salt.
- Treating migraine using the two active ingredients.
- Dose relationships and administration regimens.
- Fixed-dose oral delivery.
The commercial significance of these claims declined as generic applicants challenged or waited out the relevant patent term. Generic approval under an ANDA does not require a sponsor to reproduce the brand’s marketing strategy, but it does require the product to meet applicable sameness and bioequivalence standards.
Formulation patents
The formulation provided convenience but limited long-term exclusivity. The branded tablet used a fixed-dose combination with sumatriptan succinate and naproxen sodium. Formulation claims can delay entry when they cover a commercially necessary dosage form, but they are less powerful after:
- The central combination patent expires.
- Generic manufacturers develop bioequivalent tablets.
- Physicians accept separate generic administration as an alternative.
- Payers favor the lowest net-cost option.
There is no biosimilar pathway for this product. Sumatriptan and naproxen sodium are synthetic small molecules regulated through the ANDA pathway, not the biologics license application and biosimilar pathway.
What is the FDA regulatory and Orange Book status of Treximet?
Treximet was approved under an NDA, while generic competitors enter under ANDAs referencing the listed drug. The FDA Orange Book historically identified Treximet’s approved product and associated patent information. Once listed patents expired or ceased to block approval, the Orange Book no longer provided a meaningful barrier to multiple-source competition.[2]
The regulatory structure has four commercial consequences:
- Generic manufacturers can rely on the reference product’s safety and efficacy findings.
- Generic applicants compete primarily on price, distribution, and contracting.
- The brand must justify any price premium through adherence, access, or patient preference.
- New clinical evidence for the fixed-dose combination is difficult to monetize without additional exclusivity.
The product’s FDA-approved indication remains relevant for labeling and reimbursement, but it does not protect the brand from substitution after generic approval.
Which companies challenged Treximet patents and how did litigation affect entry?
Generic entry followed the conventional ANDA challenge framework. Applicants could certify that listed patents were expired, invalid, unenforceable, or would not be infringed. Patent litigation involving the originator and generic applicants affected the timing of market entry, while settlement terms in pharmaceutical patent disputes were not always publicly disclosed in full.
Publicly identified Treximet generic suppliers have included major generic manufacturers such as Mylan, now part of Viatris, and other ANDA sponsors. The FDA’s Drugs@FDA and Orange Book records provide the operative regulatory history for approved generic products.[2,3]
The litigation economics favored eventual generic entry because:
- The active ingredients were mature.
- The combination product had a finite patent life.
- Multiple manufacturers could manufacture the tablet.
- The originator had limited ability to create a new protected indication.
- Generic applicants could compete after the principal patent barrier expired.
No biosimilar challenger is relevant. The competitive issue is ANDA-based generic substitution.
What is the financial trajectory of Treximet and its owners?
Treximet’s financial trajectory has followed the standard pattern for a branded small-molecule combination product:
- Initial launch and physician adoption after 2008.
- Specialty-pharmaceutical commercialization and broader payer exposure.
- Ownership transfers as the product matured.
- Patent expiry and generic entry.
- Rapid erosion in branded volume and pricing.
- Residual revenue from brand loyalty, formulary position, and contracted distribution.
GlaxoSmithKline commercialized Treximet after licensing the product from Pozen. The product later moved through specialty-pharmaceutical ownership structures. Assertio Holdings acquired rights to Treximet as part of its broader migraine and specialty-pharmaceutical portfolio. Corporate filings have generally reported Treximet within broader product-revenue disclosures rather than presenting it as a standalone high-growth asset.[4,5]
Revenue exposure
Treximet is no longer comparable to a protected blockbuster. Its financial value is concentrated in:
- Residual branded prescriptions.
- Authorized generic or partnered generic arrangements.
- Specialty-pharmacy distribution.
- Net pricing after rebates and discounts.
- Low-cost manufacturing and supply continuity.
The principal revenue risks are generic substitution and declining reimbursement. A mature product can retain cash flow if manufacturing costs are low and the company controls distribution, but revenue growth is unlikely without a new formulation, a new indication, or a commercial restructuring.
Margin outlook
Gross margin generally falls after generic entry because:
- Net selling prices decline.
- Payers demand larger discounts.
- Retail and specialty-pharmacy channels gain leverage.
- Multiple manufacturers compete for formulary access.
- Brand promotional spending produces a lower return.
Manufacturing economics remain favorable if the tablet is produced through established small-molecule processes. The principal cost risk is not scientific manufacturing complexity. It is supply-chain execution, including active pharmaceutical ingredient sourcing, quality compliance, and reliable tablet production.
How strong is the current patent estate for sumatriptan and naproxen sodium?
The current patent estate is weak as a barrier to ordinary generic entry. The strongest historical claims covered the fixed-dose combination and its therapeutic use, but those claims no longer provide the protection associated with a live, unexpired primary patent.
| Patent-estate factor | Assessment |
|---|---|
| Active-ingredient novelty | Low |
| Combination-product novelty | Historically meaningful, now largely exhausted |
| Formulation protection | Limited after generic bioequivalence pathways matured |
| Method-of-use protection | Narrow commercial value after core patent expiry |
| Manufacturing barriers | Moderate operational requirements, low legal exclusivity |
| Biosimilar risk | None |
| Generic risk | High |
| Probability of sustained brand price premium | Low |
A new formulation could create a separate patent opportunity, but it would need to deliver a clinically meaningful benefit, such as faster onset, improved tolerability, lower dosing frequency, or a non-oral delivery route. A reformulation without a clear therapeutic advantage would face weak payer and physician demand.
What generic launch scenarios exist for Treximet?
Scenario one: Rapid multi-source erosion
This is the base case. Several generic suppliers compete, retail prices decline, and the brand retains only a minority of prescriptions. The combination remains available but becomes a low-growth maintenance product.
Scenario two: Brand and generic coexistence
Treximet maintains a niche among patients who value one-tablet dosing or who have established response to the branded product. The brand preserves a limited premium through patient familiarity, coupons, specialty-pharmacy support, or contracting.
Scenario three: Reformulation-led repositioning
A rights holder introduces a new delivery system or dosage form before or after generic erosion. Commercial success would depend on clinical differentiation and payer acceptance. The new product would require separate patent analysis and may not preserve the original product’s economics.
Scenario four: Discontinuation or restricted commercialization
If net revenue falls below the cost of manufacturing, regulatory maintenance, and distribution, the brand may be discontinued or maintained only through a generic or authorized-generic arrangement.
What licensing deals and ownership changes shaped the product?
Pozen developed the combination and licensed commercial rights to GlaxoSmithKline. The product later moved through specialty-pharmaceutical portfolios, reflecting the declining but still monetizable cash flow of established prescription brands. Pernix and Assertio became associated with later U.S. commercialization and portfolio ownership.[4,5]
These transactions illustrate the financial logic of mature specialty drugs. Buyers typically value:
- Remaining prescription volume.
- Net cash flow after promotional costs.
- Patent or exclusivity duration.
- Manufacturing rights.
- Distribution relationships.
- The ability to combine the product with an existing migraine sales platform.
After patent expiry, the asset’s value shifts from exclusivity to operating efficiency. Licensing economics become less dependent on scientific development and more dependent on supply cost, contracting, and channel control.
What geographic markets remain attractive?
The United States is the most important market for patent-driven analysis because FDA approval, Orange Book listing, ANDA litigation, and U.S. payer substitution determine commercial value. Outside the United States, the product faces a similar mature-market pattern:
- European markets generally favor generic substitution and national reimbursement controls.
- Canada has established triptan and NSAID alternatives.
- Emerging markets may value combination convenience but remain price-sensitive.
- Local registration, trademark rights, manufacturing approvals, and distribution relationships determine access.
- Patent expiry reduces legal barriers but does not eliminate regulatory or supply requirements.
The international opportunity is therefore volume-led rather than price-led. A supplier with low manufacturing costs and regional distribution infrastructure can compete, but the product is unlikely to support premium pricing in cost-controlled markets.
What generic entry risks exist for investors and licensees?
The principal risks are commercial rather than patent-related:
- Continued prescription migration to generic sumatriptan.
- Use of separate sumatriptan and naproxen instead of the fixed-dose tablet.
- Competition from CGRP antagonists and other newer migraine therapies.
- Payer step therapy and prior authorization.
- Price erosion from multiple ANDA-approved products.
- Retail-channel substitution.
- Supply interruption or manufacturing noncompliance.
- Limited ability to obtain new exclusivity for the existing indication.
A licensee should value the asset on post-generic cash flow, not historical branded sales. The relevant diligence focus is current net sales, prescription retention, channel mix, manufacturing cost, generic share, product availability, and any remaining contractual rights.
Key Takeaways
- Treximet is the branded fixed-dose combination of sumatriptan 85 mg and naproxen sodium 500 mg.
- FDA approved the product in 2008 under NDA 021926.
- The principal U.S. patent estate expired in the late 2010s, removing the main barrier to generic entry.
- Generic competition is high, while biosimilar risk is not applicable.
- The main substitute is generic sumatriptan used with generic naproxen.
- CGRP therapies create additional pressure in patients who need non-triptan options.
- Financial value now depends on residual brand loyalty, low-cost manufacturing, distribution, and generic or authorized-generic strategy.
- The product is a mature cash-flow asset, not a high-growth protected medicine.
- New value would require a clinically differentiated formulation, delivery system, or commercial structure.
FAQs
Is sumatriptan and naproxen sodium still patented?
The principal U.S. patent protection for the Treximet combination expired in the late 2010s. Generic competition is therefore established.
Is Treximet a biologic or biosimilar product?
No. Treximet is a small-molecule fixed-dose combination. Generic versions are approved through the ANDA pathway.
Can generic sumatriptan and naproxen replace Treximet?
They can provide the same active ingredients separately, but they do not replicate the convenience of a single fixed-dose tablet.
Why are CGRP drugs a threat to Treximet?
CGRP therapies offer a non-vasoconstrictive mechanism and are used for patients who cannot tolerate triptans, do not respond adequately, or have contraindications to triptan therapy.
What would increase the value of a Treximet-related asset?
A differentiated formulation, faster onset, improved tolerability, non-oral delivery, stronger adherence data, or a low-cost authorized-generic platform could improve commercial value.
References
-
U.S. Food and Drug Administration. (2008). Treximet prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. FDA.
-
Assertio Holdings, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
GlaxoSmithKline plc. (2014). Annual report 2013. GSK.
More… ↓

